MindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results MindWalk Holdings (Nasdaq: HYFT) reported Q3 fiscal 2026 revenue of $4.2 million, a 52% increase year‑over‑year, marking the third consecutive quarterly YoY revenue gain. US revenue doubled to $2.6 million. Gross margin was 59% in Q3 and cash totaled $14.2 million as of Jan 31, 2026.The company signed its first one‑year recurring LensAI platform contract, launched the B cell Llama nanobody platform, reported progress on dengue, GLP‑1 and influenza programs, and is designing asset‑level financing for select assets.

#HYFT MindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results

www.stocktitan.net/news/HYFT/mind-walk-hold...

MindWalk Announces B Cell Llama™, a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era MindWalk Holdings (NASDAQ: HYFT) announced B Cell Llama™, a VHH nanobody discovery platform built for bispecific, multispecific and cell therapy development. A peer-reviewed 2026 study in Biomacromolecules showed multivalent VHH formats reached sub-nanomolar potency and 10–25x activity versus monovalent forms.The study found a trivalent construct neutralized variants that escaped monovalent molecules and suggested a possible immune-priming effect. MindWalk holds first right to commercialize jointly developed IP and will layer LensAI™ to prioritize functional activity over binding metrics.

#HYFT MindWalk Announces B Cell Llama™, a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era

www.stocktitan.net/news/HYFT/mind-walk-anno...

MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight MindWalk (NASDAQ:HYFT) announced a discovery of a persistent functional constraint in influenza biology identified using its patented HYFT Deep Data technology. The company reports the HYFT-defined pattern is conserved across human influenza A (including H3N2 and H3N2 subclade K), avian A subtypes H5, H7, H9, swine-origin H1N1, and influenza B lineages Victoria and Yamagata. MindWalk says this constraint reflects biophysical requirements for infection rather than conserved sequence, and plans further preclinical and IND-enabling work with an out-licensing or strategic-partnering strategy for the program.

#HYFT MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight

www.stocktitan.net/news/HYFT/mind-walk-adva...

Leading Indicators, Wednesday January 7, 2026 – Crystal Equity Research

Small-cap stocks in new uptrend according to average directional index, Wed Jan 7th - #QUIK #SDA #WLDN #ZNTL #AEVA #BACQ #DTI #ESQ #HYFT #ICHR #LUCD #NVAX #PGEN #SB #OGN #NSP #LPG #IHD #FC #EBS #CYD #BKSY - More: crystalequityresearch.com/leading-indi... - #smallcap

MindWalk Reports Record Growth and Announces Strategic Progress on Its AI Asset Pipeline MindWalk (NASDAQ: HYFT) reported Q2 fiscal 2026 results and strategic progress on its AI-driven pipeline on December 15, 2025. Key financials: Revenue $4.1M (+54% YoY, +30% sequential), gross margin 65% (from 51%), gross profit $2.7M (+94% YoY), adjusted EBITDA loss improved to $2.4M, and operating loss excluding amortization improved to $2.8M. Cash and cash equivalents were $16.5M, including proceeds from the sale of Netherlands operations.Strategic updates: AI-designed GLP1 receptor agonist showed in vitro activation above semaglutide; a companion longevity pathway was identified; a conserved dengue epitope was discovered with preclinical planning underway; the company completed a rebrand, appointed a new CFO and CBO, closed a Netherlands divestiture for $14.3M, and initiated a Cayman structure to ringfence AI program portfolios with investor interest ahead of a January 12, 2026 strategic update.

#HYFT MindWalk Reports Record Growth and Announces Strategic Progress on Its AI Asset Pipeline

www.stocktitan.net/news/HYFT/mind-walk-repo...

MindWalk ( #NASDAQ: #HYFT ) is redefining drug discovery through bio-native AI and wet lab innovation. CEO Dr. Jennifer Bath shares how the LensAI™ platform and rebranding strategy position the company as a leader in AI-driven healthcare.

Learn more: youtu.be/07jQObacjvE?...

$60 Billion Longevity Market: MindWalk's AI Platform Creates First Dual-Pathway GLP-1 Aging Treatment MindWalk's LensAI platform discovers novel longevity pathway for GLP-1 therapy combination. Proprietary companion drug matches semaglutide efficacy. Program targets $60B market opportunity by 2030.

#HYFT MindWalk Advances AI-Designed GLP-1 Program with First-in-Class Dual-Pathway Regimen for Aging and Longevity

www.stocktitan.net/news/HYFT/mind-walk-adva...

Earnings This Week :

#CODA #HAIN #HYFT #PLAY #CSBR #HITI #FERG #EPM #FLUX #GIS #HTOO #IPHA #MANU #QSG #CBRL #NNDM #SANG #DRI #FDS #FDX #LEN #RSSS #SCHL #BTC